Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology · Autoimmune Cerebellar Ataxia

Treatment, Safety & Rehabilitation

At a Glance

Autoimmune cerebellar ataxia needs prompt, individualized treatment to protect remaining cerebellar function. Doctors may use steroids, IVIG, plasma exchange, or longer-term immune medicines; paraneoplastic cases also require cancer treatment, with rehabilitation for balance, speech, and swallowing.

Treating autoimmune cerebellar ataxia requires prompt action. The goal is to stop the immune system’s attack before it causes permanent loss of Purkinje cells—the large, specialized neurons in the cerebellum that coordinate movement [1]. Once these cells are lost, they do not grow back. This concept of remaining healthy cells is often called cerebellar reserve, and preserving it is a primary focus of your medical team [2][1].

Early Treatment and Considerations

Research shows that patients who receive treatment earlier generally have better outcomes. In one study, patients who responded well to therapy started treatment at a median of 12 months after their symptoms began, while those who did not respond waited an average of 24 months [3]. While this isn’t a strict “deadline,” it underscores the importance of calming the immune system as soon as a diagnosis is suspected [3][4].

Initial Immunotherapies: “Calming the Storm”

Specialists may use one or more therapies to calm the immune system. There is no single universal regimen, and options include [5][6]:

  1. High-Dose Corticosteroids: Typically involving Intravenous Methylprednisolone. Steroids act to rapidly suppress the immune system [7][8].
  2. Intravenous Immunoglobulin (IVIG): This treatment provides your body with healthy antibodies from donors, which can help modulate the immune response [5][7].
  3. Plasma Exchange (PLEX): Also called plasmapheresis, this process cycles your blood through a machine to physically filter out circulating proteins and antibodies [9][10].

Escalating Care: Maintenance Therapies

If first-line treatments aren’t enough, or if your symptoms return (a relapse), your doctor may suggest maintenance medications [11][12].

  • Rituximab: A specialized drug that depletes the B-cells responsible for making antibodies. It is often used for severe or relapsing cases [11][13].
  • Mycophenolate Mofetil or Azathioprine: These are daily pills that provide long-term suppression of the immune system to prevent future attacks [14][15].
  • Cyclophosphamide: A more aggressive drug reserved for rapidly progressing cases that haven’t responded to other treatments [16][17].

Medication Safety and Monitoring

Immunotherapies are potent medications. Never start, stop, or taper immunotherapy without your treating team’s guidance.

  • Corticosteroids: Can cause high blood sugar, elevated blood pressure, mood changes, insomnia, and bone density loss.
  • IVIG: Carries risks of blood clots (thrombosis), kidney injury, and aseptic meningitis.
  • Plasma Exchange (PLEX): Risks include bleeding, low blood pressure, and central line infections.
  • Maintenance Drugs (Rituximab, Mycophenolate, etc.): Can suppress bone marrow, affect liver function, and impact fertility. Rituximab carries risks of infusion reactions.
  • Infection Risk: All immunosuppressants lower your ability to fight infections. Call your doctor immediately for fevers, severe coughs, or new signs of illness.

Treatment Logic: PACA vs. PCD

The strategy changes slightly depending on whether you have Primary Autoimmune Cerebellar Ataxia (PACA) or Paraneoplastic Cerebellar Degeneration (PCD).

Feature Primary (PACA) Strategy Paraneoplastic (PCD) Strategy
Main Goal Long-term immune suppression to prevent relapses [5]. Rapidly finding and treating the underlying tumor [18].
Treatment Path Focuses on immunotherapy (Steroids, IVIG, Rituximab) [14]. Focuses on Surgery, Chemo, or Radiation plus immunotherapy [18].
Response Often shows better neurological recovery, especially if caught early [4][19]. Neurological recovery is often limited even if the cancer is cured [18].

Paraneoplastic Treatment Realities

In cases of PCD, treating the cancer is essential. However, successfully treating a tumor does not always mean your balance will return to normal [18][20]. This is because the immune system can do significant damage to the cerebellum before the tumor is ever found. In one study of patients with anti-Tr antibodies, 88% had a complete response to their cancer treatment, but only 41% saw significant neurological improvement [18]. This makes early, individualized immunotherapy important alongside cancer care to protect whatever cerebellar reserve remains [21]. 🛡️ Individuals with established cerebellar atrophy (shrinking) on their MRI may have a more difficult road to recovery, but stabilization is still a primary goal of treatment [22].

Rehabilitation

Drug therapy is only one part of care. Early physical therapy (PT) and occupational therapy (OT) are critical for fall prevention and mobility aids, while speech-language pathology (SLP) helps with swallowing safety and speech [19].

Common questions in this guide

What treatments are used for autoimmune cerebellar ataxia?
Initial treatment may include high-dose corticosteroids, intravenous immunoglobulin, or plasma exchange. If symptoms are severe, return after treatment, or do not improve enough, doctors may use longer-term medicines such as rituximab, mycophenolate mofetil, azathioprine, or cyclophosphamide.
Why is early treatment important for autoimmune cerebellar ataxia?
Early treatment aims to stop the immune attack before more cerebellar nerve cells are permanently lost. People treated sooner generally have better outcomes, although there is no single deadline that determines whether recovery is possible.
How does treatment differ between PACA and paraneoplastic cerebellar degeneration?
Primary autoimmune cerebellar ataxia is mainly treated with immune therapies to control the attack and prevent relapses. Paraneoplastic cerebellar degeneration also requires finding and treating the underlying cancer, often with surgery, chemotherapy, or radiation, alongside individualized immune treatment.
What safety problems can autoimmune ataxia treatments cause?
Steroids can affect blood sugar, blood pressure, sleep, mood, and bone strength. IVIG may cause blood clots or kidney problems, plasma exchange can cause bleeding or low blood pressure, and immune-suppressing medicines can increase infection risk and affect blood counts or liver function.
Can rehabilitation help people with autoimmune cerebellar ataxia?
Yes. Physical therapy can support balance, fall prevention, and mobility, while occupational therapy can help with daily activities and adaptive equipment. Speech-language therapy can address speech and swallowing safety, including when some neurological damage is permanent.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Non-specific autoimmune cerebellar ataxia with characteristic antibodies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I still within the window where my cerebellum has enough reserve to recover?
  2. 2.If I don't respond to steroids, what is the specific plan—IVIG, plasma exchange, or both?
  3. 3.Given my specific antibody, am I more likely to need long-term maintenance therapy like Rituximab or Mycophenolate?
  4. 4.How will we objectively measure if the treatment is working?
  5. 5.For my PCD, how will my oncology team and neurology team coordinate my cancer treatment and my immunotherapy?

References

References (22)
  1. 1

    Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.

    Mitoma H, Manto M, Hampe CS

    Current neuropharmacology 2019; (17(1)):33-58 doi:10.2174/1570159X16666180917105033.

    PMID: 30221603
  2. 2

    Time Is Cerebellum.

    Mitoma H, Manto M, Hampe CS

    Cerebellum (London, England) 2018; (17(4)):387-391 doi:10.1007/s12311-018-0925-6.

    PMID: 29460203
  3. 3

    Suspected autoimmune cerebellar ataxia: Predictors of immunotherapy response and diagnosis reclassification to neurodegenerative disease.

    Nakamura N, Ii Y, Hirata Y, et al.

    Journal of the neurological sciences 2026; (488()):126048 doi:10.1016/j.jns.2026.126048.

    PMID: 42269360
  4. 4

    Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults.

    Jones AL, Flanagan EP, Pittock SJ, et al.

    JAMA neurology 2015; (72(11)):1304-12 doi:10.1001/jamaneurol.2015.2378.

    PMID: 26414229
  5. 5

    Anti-Glutamic Acid Decarboxylase 65 (GAD65) Antibodies and Neurological Syndromes.

    Mohammadzadeh O, Fahimzadeh N, Elhami F, Shobeiri SS

    The journal of gene medicine 2025; (27(10)):e70039 doi:10.1002/jgm.70039.

    PMID: 41038708
  6. 6

    Guidelines for treatment of immune-mediated cerebellar ataxias.

    Mitoma H, Hadjivassiliou M, Honnorat J

    Cerebellum & ataxias 2015; (2()):14 doi:10.1186/s40673-015-0034-y.

    PMID: 26561527
  7. 7

    Anti-Ma2 Antibody-Associated Paraneoplastic Cerebellar Degeneration Mimicking the Cerebellar Ataxic Subtype of Hashimoto's Encephalopathy: A Case Report.

    Okitsu M, Nojiri S, Kawazoe T, et al.

    Case reports in neurological medicine 2026; (2026()):1445118 doi:10.1155/crnm/1445118.

    PMID: 42293301
  8. 8

    A case of autoimmune cerebellar ataxia associated with anti-neurochondroitin antibody.

    Yang J, Xu Y, Huang Y

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(5)).

    PMID: 41973249
  9. 9

    Case report and literature analysis: Autoimmune cerebellar ataxia associated with homer-3 antibodies.

    Wu Q, Gong B, Jiang A, Qin X

    Frontiers in neurology 2022; (13()):951659 doi:10.3389/fneur.2022.951659.

    PMID: 35959384
  10. 10

    Treatment-responsive primary autoimmune cerebellar ataxia in a patient with IgG and IgM anticerebellar antibodies.

    Jaffe SL, Carlson NG, Peterson LK, Greenlee JE

    European journal of neurology 2021; (28(5)):1771-1773 doi:10.1111/ene.14659.

    PMID: 33253468
  11. 11

    Anti-Sez6L2 antibody-associated autoimmune cerebellar ataxia: a rare case with implications of rituximab therapy.

    Gao Y, Duan R

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(5)).

    PMID: 41998399
  12. 12

    Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.

    Liu M, Ren H, Wang L, et al.

    Journal of neurology 2024; (271(3)):1072-1079 doi:10.1007/s00415-023-12128-9.

    PMID: 38141127
  13. 13

    Autoimmune cerebellar ataxia with anti-Homer3 antibodies associated with herpesvirus infection: a case report and literature review.

    Song DJ, Dong R, Liu YM, et al.

    Frontiers in immunology 2025; (16()):1709326 doi:10.3389/fimmu.2025.1709326.

    PMID: 41601644
  14. 14

    Treatment of Primary Autoimmune Cerebellar Ataxia with Mycophenolate.

    Hadjivassiliou M, Grunewald RA, Shanmugarajah PD, et al.

    Cerebellum (London, England) 2020; (19(5)):680-684 doi:10.1007/s12311-020-01152-4.

    PMID: 32524518
  15. 15

    Immunotherapies for the Effective Treatment of Primary Autoimmune Cerebellar Ataxia: a Case Series.

    Li J, Deng B, Song W, et al.

    Cerebellum (London, England) 2023; (22(6)):1216-1222 doi:10.1007/s12311-022-01496-z.

    PMID: 36434494
  16. 16

    Anti-neurochondrin antibody as a biomarker in primary autoimmune cerebellar ataxia-a case report and review of the literature.

    Schwarzwald A, Salmen A, León Betancourt AX, et al.

    European journal of neurology 2023; (30(4)):1135-1147 doi:10.1111/ene.15648.

    PMID: 36437687
  17. 17

    SEZ6L2 Antibody-Associated Cerebellar Ataxia Responsive to Sequential Immunotherapy.

    Mehdiyeva A, Hietaharju A, Sipilä J

    Neurology(R) neuroimmunology & neuroinflammation 2022; (9(2)) doi:10.1212/NXI.0000000000001131.

    PMID: 35031588
  18. 18

    Anti-Tr/DNER Antibody-Associated Cerebellar Ataxia: a Systematic Review.

    Campana IG, Silva GD

    Cerebellum (London, England) 2022; (21(6)):1085-1091 doi:10.1007/s12311-021-01346-4.

    PMID: 34817790
  19. 19

    Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia.

    Damato V, Papi C, Spagni G, et al.

    European journal of neurology 2022; (29(2)):564-572 doi:10.1111/ene.15161.

    PMID: 34710286
  20. 20

    TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration.

    Do LD, Gupton SL, Tanji K, et al.

    Cerebellum (London, England) 2019; (18(2)):245-254 doi:10.1007/s12311-018-0987-5.

    PMID: 30350014
  21. 21

    Clinical Spectrum, Therapeutic Outcomes and Prognostic predictors in Paraneoplastic Neurological Syndromes - Experiences from a Tertiary Care Center in India.

    Vijayaraghavan A, Alexander PT, Nair AV, et al.

    Annals of Indian Academy of Neurology 2021; (24(1)):32-39 doi:10.4103/aian.AIAN_975_20.

    PMID: 33911377
  22. 22

    Autoantibodies against eukaryotic translation elongation factor 1 delta in two patients with autoimmune cerebellar ataxia.

    Guo L, Ren H, Fan S, et al.

    Frontiers in immunology 2023; (14()):1289175 doi:10.3389/fimmu.2023.1289175.

    PMID: 38332912

This page is for informational purposes only and does not constitute medical advice. Your neurologist, oncologist, and rehabilitation team should individualize treatment and safety monitoring for your situation.